Signet ring cell-like diffuse large B-cell lymphoma involving the breast: a case report - BMC Women's Health
Source : https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-023-02285-4
Background Diffuse large B-cell lymphoma (DLBCL) with signet ring cell components is extremely rare. Here, we present a case of DLBCL with signet ring cell components involving the breast, which...
Conclusions/Relevance: Here, we present a case of DLBCL with signet ring cell components involving the breast, which can be easily confused with invasive lobular carcinoma of the breast or metastatic signet ring cell carcinoma of gastrointestinal origin.
Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-023-05165-x
Extranodal involvement predicts poor outcomes of diffuse large B cell lymphoma (DLBCL), but the impact of the metabolic tumor burden (MTV) of extranodal sites using positron emission tomography has not...
Conclusions/Relevance: When both the number and MTV of extranodal involvements were used as covariables, extranodal MTV remained a significant predictor of OS (HR 1.070, 95%CI 1.017–1.127, P = 0.009), but the number of extranodal sites did not. Extranodal MTV potentially had a more significant role on prognosis than nodal MTV. When...
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36929591/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: CD5-positive (CD5+) DLBCL is characterized by aggressive clinical characteristics and frequent CNS relapse. In 2020, we reported the results of the primary analysis of a phase 2 study of dose-adjusted (DA)-EPOCH-R combined with high-dose (HD)-MTX (DA-EPOCH-R/HD-MTX) (PEARL5 study) with a median follow-up of...
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas - Nature Materials
Source : https://www.nature.com/articles/s41563-023-01495-3
Activated B-cell-like diffuse large B-cell lymphomas (ABC-DLBCLs) are characterized by constitutive activation of nuclear factor κB driven by the B-cell receptor (BCR) and Toll-like receptor (TLR) pathways. However, BCR-pathway-targeted therapies...
Conclusions/Relevance: Our studies define the complex crosstalk between malignant ABC-DLBCL cells and Ly-TME, and provide rational combinatorial therapies that rescue Ly-TME-mediated attenuation of treatment response to MALT1 inhibitors.
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36875713/
This work describes the safety and efficacy of a new pharmaceutical pathway that could provide a treatment option for a subset of patients with a critical unmet therapeutic need. The...
Conclusions: Significance: This work describes the safety and efficacy of a new pharmaceutical pathway that could provide a treatment option for a subset of patients with a critical unmet therapeutic need. The study drug, MT-3724, is capable of targeting B-cell lymphomas via a unique, potent cell-killing mechanism that appears to be promising.